Clinical trial
A Randomized, Open-label, Controlled, Multicenter Phase II Trial of Anrotenib Plus Toripalimab Versus Toripalimab for Following Treatment of Advanced Esophageal Squamous Cell Carcinoma After Chemotherapy Failure
NCT04229849 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Controlled, Multicenter Phase II Trial of Anrotenib Plus Toripalimab Versus Toripalimab for Following Treatment of Advanced Esophageal Squamous Cell Carcinoma After Chemotherapy Failure
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2020
- Completion date
- January 31, 2022
- Enrollment
- 164 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.